GLPwatch
Comparison of the injection-site experience of semaglutide in a single-dose and a multidose pen-injector.
Diabetes Obes Metab · 2022
Last updated 2026-07-18| Journal | Diabetes Obes Metab, 2022 |
|---|---|
| Citations | 4 |
| Relative citation ratio | 0.30 |
| NIH percentile | 18 |
| Molecules | semaglutide |
Full record and abstract on PubMed 35434913 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.